Celldex Therapeutics, Inc. CLDX
Set alert
At close · Oct 30
After hours · Oct 30, 4:27 PM ET
- YTD
- +10.82%
- 1 year
- +15.77%
- Open
- 29.70
- Prev close
- 29.89
- Mkt cap
- 2.36B
- Vol
- 870.78K
- Avg vol
- 1.35M
- EPS
- -4.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 29.20
- High
- 30.12
- Forward P/E
- -7.08
- Beta
- 0.90
- Short ratio
- 4.27
- Inst. own
- 109.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 34.25
- 200-d avg
- 32.63
- 1y target
- 63.07
5D chart
Signals (100)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:45 PM | 4 days ago |
| RSI: Oversold | Oct 28, 12:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:55 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:35 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:00 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:40 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 10:45 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
2 weeks ago prnewswire.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation…
3 weeks ago defenseworld.net
Head-To-Head Analysis: Senti Biosciences (NASDAQ:SNTI) and Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Senti Biosciences (NASDAQ: SNTI - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $64 price target.
1 month ago defenseworld.net
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Down – What’s Next?
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) gapped down before the market opened on Tuesday. The stock had previously closed at $37.89, but opened at $36.60. Celldex Therapeutics…
-
1 month ago benzinga.com
Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88
Leerink Partners analyst Thomas Smith maintains Celldex Therapeutics (NASDAQ:CLDX) with a Outperform and raises the price target from $70 to $88.
-
1 month ago benzinga.com
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $50 to $57.
1 month ago defenseworld.net
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
Celldex Therapeutics (NASDAQ: CLDX) reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained…
1 month ago seekingalpha.com
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript
1 month ago benzinga.com
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
1 month ago benzinga.com
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic…
1 month ago benzinga.com
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64
HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $42 to $64.
1 month ago marketbeat.com
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
Celldex Therapeutics NASDAQ: CLDX reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained…
1 month ago zacks.com
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
-
1 month ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72
Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $61 to $72.
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million. Greenland Mines (NASDAQ:GRML) shares rose…
1 month ago reuters.com
Celldex's skin disease drug meets goals in two late-stage trials
Celldex Therapeutics said on Tuesday its experimental drug for a skin disease met the main and secondary goals of two late-stage trials.
-
1 month ago benzinga.com
Celldex Reports Topline Results From The Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Trials Evaluating Two Doses Of Barzolvolimab In Patients With Chronic Spontaneous Urticaria; Results Showed Rapid, Profound, Sustained Efficacy, Supporting Barzolvolimab’s Potential To Be A Transformational Therapy In CSU
EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groupsClinically meaningful and statistically significant benefit demonstrated in…
1 month ago globenewswire.com
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSU EMBARQ-CSU1 and -CSU2 met primary and all key…
1 month ago defenseworld.net
Head-To-Head Survey: Celldex Therapeutics (NASDAQ:CLDX) & Bicycle Therapeutics (NASDAQ:BCYC)
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare…
1 month ago defenseworld.net
Engineers Gate Manager LP Takes $1.26 Million Position in Celldex Therapeutics, Inc. $CLDX
Engineers Gate Manager LP acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ: CLDX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
1 month ago defenseworld.net
Head-To-Head Comparison: Precigen (NASDAQ:PGEN) and Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Precigen (NASDAQ: PGEN - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two…
1 month ago defenseworld.net
Seres Therapeutics (NASDAQ:MCRB) and Celldex Therapeutics (NASDAQ:CLDX) Head to Head Review
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Seres Therapeutics (NASDAQ: MCRB - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two…
-
1 month ago benzinga.com
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $46 to $50.
1 month ago globenewswire.com
Celldex to Present at Upcoming Investor Conference
HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on…
2 months ago prnewswire.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation…
2 months ago defenseworld.net
California State Teachers Retirement System Acquires 21,233 Shares of Celldex Therapeutics, Inc. $CLDX
California State Teachers Retirement System raised its holdings in Celldex Therapeutics, Inc. (NASDAQ: CLDX) by 36.4% during the undefined quarter, according to the company in its most recent…
-
2 months ago benzinga.com
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $40 to $46.
-
2 months ago benzinga.com
Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $53.
2 months ago zacks.com
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago.
-
2 months ago benzinga.com
Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.15 percent. This is a 10.59 percent decrease over losses…
-
3 months ago benzinga.com
Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72
Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $72.
3 months ago zacks.com
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
3 months ago defenseworld.net
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
Celldex Therapeutics (NASDAQ: CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the…
-
3 months ago benzinga.com
Wells Fargo Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $48
Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $54 to $48.
-
3 months ago benzinga.com
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $40
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $44 to $40.
3 months ago benzinga.com
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fall 16% in pre-market trading.
-
3 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $61
Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $67 to $61.
3 months ago benzinga.com
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study
Celldex has discontinued its Phase 2 trial of barzolvolimab for prurigo nodularis after failing to meet primary and secondary endpoints.
-
3 months ago benzinga.com
Canaccord Genuity Maintains Buy on Celldex Therapeutics, Lowers Price Target to $60
Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $62 to $60.
-
3 months ago benzinga.com
Celldex Reports Topline Results From Phase 2 Study Of Barzolvolimab In Prurigo Nodularis; Study Did Not Meet Key Efficacy Objectives
Study did not meet key efficacy objectivesFavorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimenProfound systemic mast cell…
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
10 months ago benzinga.com
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
11 months ago benzinga.com
Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday?
Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
1 year ago benzinga.com
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
1 year ago benzinga.com
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session